📈
7×
GHR Upregulation
Growth hormone receptor by day 3
Research Hub
BPC-157 Research
Dedicated research overview for BPC-157, including mechanisms, applications, amount context, and sources.
✅
7/12
Human Patients
Reported pain relief >6 months
📚
200+
Publications
Peer-reviewed studies since 1991
🛡️
No LD50
Achieved
No lethal dose found in toxicity studies
⏱️
14-21 days
Typical Timeline
For observable effects in studies
How BPC-157 Works
The science, simplified
Multi-Pathway Mechanism
BPC-157 works through several interconnected biological pathways that promote healing and tissue repair. It activates cellular repair mechanisms, supports blood vessel formation, and modulates inflammation.
VEGF
Primary
VEGFR2 Pathway
- Promotes new blood vessel formation
- Increases blood flow to injured areas
- Activates endothelial cell proliferation
NO
Modulatory
Nitric Oxide System
- Dilates blood vessels
- Improves oxygen delivery
- Protects against ischemia
GF
Supportive
Growth Factor Pathways
- Enables cell migration to injury sites
- Promotes cell survival and growth
- Activates tissue repair genes
Key mechanism
VEGFR2-Akt-eNOS Signaling Cascade
BPC-157 activates the VEGFR2 pathway, promoting receptor internalization and downstream signaling. This triggers the Akt-eNOS cascade and increased nitric oxide production in preclinical models.
VEGFR2 Expression↑ Upregulated
Receptor Internalization↑ Enhanced
Akt Phosphorylation↑ Time-dependent
eNOS Activation↑ Increased NO
Growth pathway
GHR Upregulation & Tissue Repair
Preclinical findings report increased Growth Hormone Receptor (GHR) expression and enhanced migration-related signaling in tissue-repair models.
GHR Expression (Day 3)7× increase
FAK Phosphorylation↑ Dose-dependent
Paxillin Activation↑ Enhanced
Cell Migration↑ 70% faster
Research Applications
Tendon
Healing
Enhanced fibroblast outgrowth and collagen synthesis
J Applied Physiology
GI Tract
Protection
Stable in gastric juice for 24+ hours
Gut and Liver Journal
Neuro
Protection
Brain injury and dopamine/serotonin modulation studied
Curr Neuropharmacology
Bone
Healing
Enhanced bone defect healing in rabbit studies
J Orthop Research
Amount Information from Research
BPC-157 has been administered via multiple routes in research settings. Most animal studies use μg/kg or ng/kg amounts, while the Phase 1 human trial tested oral tablets.
Human clinical trial
Phase 1 Clinical Trial (NCT02637284)
- • 1mg, 3mg, or 6mg oral tablet
- • Three times daily × 14 days in one arm
- • Status: Completed (2016)
Preclinical research
Preclinical Amount (Animal Studies)
- • 10 μg/kg common range
- • 10 ng/kg ultra-low dose reported
- • 500 μg/kg safety range reported